34.25
Bridgebio Pharma Inc stock is traded at $34.25, with a volume of 2.97M.
It is up +2.64% in the last 24 hours and down -5.96% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$33.37
Open:
$33.09
24h Volume:
2.97M
Relative Volume:
1.00
Market Cap:
$6.50B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-14.21
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+2.73%
1M Performance:
-5.96%
6M Performance:
+26.43%
1Y Performance:
+18.72%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BBIO
Bridgebio Pharma Inc
|
34.25 | 6.33B | 217.77M | -438.86M | -456.33M | -2.41 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-31-25 | Initiated | Redburn Atlantic | Buy |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Oct-03-24 | Initiated | Oppenheimer | Perform |
Sep-04-24 | Initiated | Piper Sandler | Overweight |
Mar-21-24 | Resumed | Raymond James | Outperform |
Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Nov-07-23 | Initiated | Citigroup | Buy |
Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
Apr-19-23 | Initiated | Evercore ISI | Outperform |
Feb-06-23 | Initiated | Cowen | Outperform |
Dec-27-21 | Reiterated | Mizuho | Buy |
Dec-27-21 | Reiterated | SVB Leerink | Outperform |
Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
May-21-21 | Initiated | UBS | Buy |
Mar-22-21 | Reiterated | Goldman | Buy |
Feb-22-21 | Resumed | JP Morgan | Overweight |
Feb-09-21 | Resumed | Goldman | Buy |
Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
Jun-25-20 | Initiated | BofA/Merrill | Neutral |
May-19-20 | Initiated | BTIG Research | Buy |
Apr-13-20 | Initiated | H.C. Wainwright | Buy |
Feb-19-20 | Initiated | Mizuho | Buy |
Jul-26-19 | Initiated | Raymond James | Outperform |
Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
Jul-22-19 | Initiated | Goldman | Buy |
Jul-22-19 | Initiated | JP Morgan | Overweight |
Jul-22-19 | Initiated | Jefferies | Buy |
Jul-22-19 | Initiated | Piper Jaffray | Overweight |
Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria
Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com
Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com
BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus
Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan
BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria
BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - marketscreener.com
BridgeBio’s acoramidis shows promise in ATTR-CM study - Investing.com
BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients - Nasdaq
Breakthrough ATTR-CM Study: Higher TTR Levels from Acoramidis Directly Predict 31% Better Survival Rates - Stock Titan
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - Yahoo Finance
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - MSN
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - Yahoo
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance
Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com
Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey
BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus
BridgeBio launches landmark ATTR prevention study - Investing.com Australia
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - The Manila Times
BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria
BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus
BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
(BBIO) Trading Report - news.stocktradersdaily.com
Raymond James Financial Inc. Invests $456,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times
Recursion cuts nearly half of its pipeline - statnews.com
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO St - GuruFocus
BridgeBio Pharma Stock (BBIO) Jumps on Strong Drug Launch - The Globe and Mail
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks In The US Market May 2025 - simplywall.st
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Kumar Neil | Chief Executive Officer |
May 19 '25 |
Sale |
33.33 |
26,156 |
871,764 |
217,404 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):